Phanes Therapeutics to Present Updated Spevatamig Phase 2 Results for Metastatic Pancreatic Cancer at ASCO 2026

Key Takeaways

• Phanes Therapeutics will present updated Phase 2 results of spevatamig (PT886) in combination with chemotherapy for frontline metastatic pancreatic cancer treatment
• The presentation will occur at the ASCO Annual Meeting from May 29 - June 2, 2026 in Chicago
• This represents progress in developing new treatment options for metastatic pancreatic ductal adenocarcinoma, one of the most challenging cancers to treat

---

SAN DIEGO - Phanes Therapeutics, Inc., a clinical-stage biotechnology company specializing in oncology drug discovery and development, announced it will present updated Phase 2 clinical trial results for spevatamig (PT886) at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

The presentation will focus on spevatamig’s performance when combined with chemotherapy as a frontline treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCO Annual Meeting is scheduled for May 29 through June 2, 2026, in Chicago.

Addressing Critical Medical Need

Pancreatic ductal adenocarcinoma represents one of the most aggressive forms of cancer, with metastatic cases presenting particularly challenging treatment scenarios. Current frontline therapies for mPDAC have limited efficacy, making the development of novel combination approaches a critical priority in oncology research.

Spevatamig (PT886) represents Phanes Therapeutics’ innovative approach to addressing this unmet medical need. The drug is being evaluated in combination with standard chemotherapy regimens to potentially improve outcomes for patients with newly diagnosed metastatic disease.

IntelligenceRegulatory Impact▾

FDA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in the Americas. Regulatory relevance reads medium for pharmaceutical intelligence. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.

Clinical Development Progress

The upcoming ASCO presentation will provide updated data from the ongoing Phase 2 clinical trial, offering insights into the safety and efficacy profile of the spevatamig-chemotherapy combination. This data will be crucial for understanding the drug’s potential role in the treatment landscape for metastatic pancreatic cancer.

Phanes Therapeutics continues to advance its oncology pipeline, with spevatamig representing a key asset in the company’s efforts to develop innovative cancer treatments. The ASCO presentation will provide the medical community with important updates on this promising therapeutic approach.

The pharmaceutical industry and oncology community will closely monitor these results, as new treatment options for metastatic pancreatic cancer remain a significant area of unmet medical need.

---

Frequently Asked Questions

What is spevatamig and how does it work?

Spevatamig (PT886) is an investigational oncology drug being developed by Phanes Therapeutics. It is being studied in combination with chemotherapy for treating metastatic pancreatic ductal adenocarcinoma, though specific mechanism details have not been disclosed in this announcement.

When will spevatamig be available to patients?

Spevatamig is currently in Phase 2 clinical trials and is not yet approved for commercial use. The timeline for potential approval will depend on the results of ongoing and future clinical studies, regulatory review processes, and successful completion of all required trial phases.

How significant is this development for pancreatic cancer treatment?

Metastatic pancreatic ductal adenocarcinoma has very limited treatment options and poor outcomes with current therapies. Any new treatment approach that shows promise in clinical trials represents potentially significant progress for patients facing this challenging diagnosis.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update